Print（PDF/136KB） Mar. 25, 2026 Finances

Notice Concerning Non-operating Income Recorded in the Company’s Non-consolidated Financial Statements (Japanese GAAP)

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; Securities Code: 4506, Prime Market of TSE; the “Company”) announced today that it expects to record non-operating income in its non-consolidated financial statements (Japanese GAAP) for the year ending March 31, 2026 (April 1, 2025 to March 31, 2026). There will be no impact on consolidated profit or loss.

1. Details of Non-operating Income

Sumitomo Pharma Switzerland GmbH, one of the Company’s consolidated subsidiaries, has decided to pay dividends. Accordingly, the Company will record dividend income of 48,340 million yen under interest and dividend income (non-operating income) in its non-consolidated financial statements for the year ending March 31, 2026.

2. Impact on the Company’s Financial Results

The above dividend income will have no impact on consolidated profit or loss, as it will be eliminated in the consolidated financial statements.

Disclaimer Regarding Forward-looking Statements

The statements made in this press release contain forward-looking statements based on management's assumptions and beliefs in light of information available as of the day of this release, which involve both known and unknown risks and uncertainties. Actual results of those matters covered in the forward-looking statements including financial forecast may differ materially from those contained in this release, due to a number of factors.